A voxel-based PET investigation of the long-term effects of "ecstasy" consumption on brain serotonin transporters

American Journal of Psychiatry

Volumn 161, Issue 7, 2004, Pages 1181-1189

  Buchert, Ralph ^a   Thomasius, Rainer ^a   Wilke, Florian ^a   Petersen, Kay ^a   Nebeling, Bruno ^a   Obrocki, Jost ^a   Schulze, Oliver ^a   Schmidt, Ulrich ^a   Clausen, Malte ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; CANNABIS; CARBON 11; COCAINE; LIGAND; LYSERGIDE; NICOTINE; PSILOCYBINE; SEROTONIN TRANSPORTER;

ADULT; ANAMNESIS; ARTICLE; BIOAVAILABILITY; BRAIN STEM; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; DRUG USE; FEMALE; FOREBRAIN; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; OCCIPITAL CORTEX; PARAMETRIC TEST; POLYPHARMACY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; STANDARD; SUBICULUM; TEMPORAL LOBE; THALAMUS;

ADULT; BRAIN; CARBON RADIOISOTOPES; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOQUINOLINES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; SEROTONIN AGENTS; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3042742015     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.7.1181     Document Type: Article

References (30)

1. Ricaurte GA, Finnegan KT, Irwin I, Langston JW: Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann NY Acad Sci 1990; 600:699-710
2. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE: Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 2000; 98:15-28
3. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS: Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 2000; 55:294-296
4. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B: Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl) 2000; 148:322-324
5. Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M: Long-term effects of ecstasy abuse on the human brain studied by FDG PET. Nucl Med Commun 2001; 22:889-897
6. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet 1998; 352:1433-1437
7. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 1999; 175:63-69
8. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W: Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001;358:1864-1869
9. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J: Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry 2001; 58:901-906
10. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M: Long-term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44:375-384
11. Kish SJ: How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 2002; 71:845-855
12. Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA: Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002; 43:678-692
13. 11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab 2000; 20:253-262
14. 11C]McN5652. J Nucl Med 2000; 41:1465-1477
15. Ditton J: Hair testing: just how accurate is it? Surveillance & Society 2002; 1:86-101
16. Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S, Kung HF: Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 1996; 37:513-520
17. Buchert R, Wilke F, van den Hoff J, Mester J: Improved statistical power of the multilinear reference tissue approach to the quantification of neuroreceptor ligand binding by regularization. J Cereb Blood Flow Metab 2003; 23:612-620
18. 3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry 1988; 24: 299-309
19. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14:982-994
20. Hesse S, Barthel H, Murai T, Muller U, Muller D, Seese A, Kluge R, Sabri O: Is correction for age necessary in neuroimaging studies of the central serotonin transporter? Eur J Nucl Med Mol Imaging 2003; 30:427-430
21. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB: Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000; 157:1134-1140
22. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290:136-145
23. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB: Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149:159-163
24. Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE: McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 1988; 247:1032-1038
25. Hewitt KE, Green AR: Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("Ecstasy") to rats. Neuropharmacology 1994; 33:1589-1595
26. Liechti ME, Baumann C, Gamma A, Vollenweider FX: Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22:513-521
27. 123I]beta- CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001; 41:275-284
28. Heinz A, Ragan P, Jones DW, Hommer D, Williams W, Knable MB, Gorey JG, Doty L, Geyer C, Lee KS, Coppola R, Weinberger DR, Linnoila M. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 1998; 155:1544-1549
29. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A: Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003; 167:85-96
30. Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT: Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: a simulation study. Neuroimage 1999; 10:397-407